journal
https://read.qxmd.com/read/38477966/intraventricular-carv3-team-e-t-cells-in-recurrent-glioblastoma
#1
JOURNAL ARTICLE
Bryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, Mark B Leick, Christopher W Mount, Leonora Balaj, Sarah Nikiforow, Bob S Carter, William T Curry, Kathleen Gallagher, Marcela V Maus
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects...
March 13, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38466616/of-aspirin-preeclampsia-and-racism
#2
JOURNAL ARTICLE
David A Sacks, Marc H Incerpi
New England Journal of Medicine, Volume 390, Issue 11, Page 968-969, March 2024.
March 9, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38466614/shift-in-the-night
#3
JOURNAL ARTICLE
Margo A Peyton
New England Journal of Medicine, Volume 390, Issue 11, Page 970-971, March 2024.
March 9, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38466610/green-dialysis-effluent-and-plasma
#4
JOURNAL ARTICLE
Bao-Ping Xu, Xiao-Tao Wang
New England Journal of Medicine, Volume 390, Issue 11, March 2024.
March 9, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38446638/back-to-the-future-in-alabama
#5
JOURNAL ARTICLE
R Alta Charo
No abstract text is available yet for this article.
March 6, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38436406/-ridding-the-race-of-his-defective-blood-eugenics-in-the-journal-1906-1948
#6
JOURNAL ARTICLE
Paul A Lombardo
New England Journal of Medicine, Volume 390, Issue 10, Page 869-873, March 2024.
March 2, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38436385/gastric-syphilis
#7
JOURNAL ARTICLE
Yulian Wang, Jianhua Wu
New England Journal of Medicine, Volume 390, Issue 10, March 2024.
March 2, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38416423/the-end-of-b-yamagata-influenza-transmission-transitioning-from-quadrivalent-vaccines
#8
JOURNAL ARTICLE
Arnold S Monto, Maria Zambon, Jerry P Weir
No abstract text is available yet for this article.
February 28, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38407394/omalizumab-for-the-treatment-of-multiple-food-allergies
#9
JOURNAL ARTICLE
Robert A Wood, Alkis Togias, Scott H Sicherer, Wayne G Shreffler, Edwin H Kim, Stacie M Jones, Donald Y M Leung, Brian P Vickery, J Andrew Bird, Jonathan M Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros-Saylan, Alkaz Uddin, Agustin Calatroni, Charmaine Marquis Huckabee, Nicole H Rogers, Nancy Yovetich, Jennifer Dantzer, Kim Mudd, Julie Wang, Marion Groetch, David Pyle, Corinne A Keet, Michael Kulis, Sayantani B Sindher, Andrew Long, Amy M Scurlock, Bruce J Lanser, Tricia Lee, Christopher Parrish, Terri Brown-Whitehorn, Amanda K Rudman Spergel, Maria Veri, Sanaz Daneshfar Hamrah, Erica Brittain, Julian Poyser, Lisa M Wheatley, R Sharon Chinthrajah
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients with multiple food allergies. Persons 1 to 55 years of age who were allergic to peanuts and at least two other trial-specified foods (cashew, milk, egg, walnut, wheat, and hazelnut) were screened...
February 25, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38407311/options-for-multiple-food-allergies-food-avoidance-or-pharmacologic-treatment
#10
EDITORIAL
Gary W K Wong
New England Journal of Medicine, Volume 390, Issue 10, Page 946-948, March 2024.
February 25, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38407284/partnering-to-enhance-clinical-trial-retention-of-black-men
#11
JOURNAL ARTICLE
Timiya S Nolan, John Gregory, Joshua J Joseph
New England Journal of Medicine, Volume 390, Issue 9, Page 778-779, February 2024.
February 24, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38407267/medically-tailored-meals-to-address-the-health-consequences-of-food-insecurity
#12
JOURNAL ARTICLE
Seth A Berkowitz, Jean Terranova
New England Journal of Medicine, Volume 390, Issue 9, Page 775-776, February 2024.
February 24, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38407253/a-salon-based-intervention-to-improve-prep-uptake-among-black-women
#13
JOURNAL ARTICLE
Schenita D Randolph, Ragan Johnson
New England Journal of Medicine, Volume 390, Issue 9, Page 776-777, February 2024.
February 24, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38393328/benralizumab-versus-mepolizumab-for-eosinophilic-granulomatosis-with-polyangiitis
#14
JOURNAL ARTICLE
Michael E Wechsler, Parameswaran Nair, Benjamin Terrier, Bastian Walz, Arnaud Bourdin, David R W Jayne, David J Jackson, Florence Roufosse, Lena Börjesson Sjö, Ying Fan, Maria Jison, Christopher McCrae, Sofia Necander, Anat Shavit, Claire Walton, Peter A Merkel
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks...
February 23, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38381664/a-phase-3-trial-of-seladelpar-in-primary-biliary-cholangitis
#15
JOURNAL ARTICLE
Gideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, Andreas E Kremer, John M Vierling, Kris V Kowdley, Cynthia Levy, Alejandra Villamil, Alma L Ladrón de Guevara Cetina, Ewa Janczewska, Ehud Zigmond, Sook-Hyang Jeong, Yusuf Yilmaz, Yiannis Kallis, Christophe Corpechot, Peter Buggisch, Pietro Invernizzi, Maria Carlota Londoño Hurtado, Sandrin Bergheanu, Ke Yang, Yun-Jung Choi, Daria B Crittenden, Charles A McWherter
BACKGROUND: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits. METHODS: In this phase 3, 12-month, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients who had had an inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid to receive oral seladelpar at a dose of 10 mg daily or placebo...
February 21, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38381658/advancing-second-line-treatment-for-primary-biliary-cholangitis
#16
EDITORIAL
David N Assis
New England Journal of Medicine, Volume 390, Issue 9, Page 853-854, February 2024.
February 21, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38375891/childhood-obesity-prevention-focusing-on-population-level-interventions-and-equity
#17
JOURNAL ARTICLE
Steven L Gortmaker, Sara N Bleich, David R Williams
New England Journal of Medicine, Volume 390, Issue 8, Page 681-683, February 2024.
February 17, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38375884/what-is-a-mentor
#18
JOURNAL ARTICLE
Suzanne Koven
New England Journal of Medicine, Volume 390, Issue 8, Page 683-685, February 2024.
February 17, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38345569/ethical-issues-in-providing-care-in-safety-net-health-systems
#19
JOURNAL ARTICLE
Dave A Chokshi, Frederick P Cerise
New England Journal of Medicine, Volume 390, Issue 7, Page 581-584, February 2024.
February 10, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38314846/interstitial-cystitis-in-sj%C3%A3-gren-s-syndrome
#20
JOURNAL ARTICLE
Hirotaka Yamamoto, Yoshinori Taniguchi
New England Journal of Medicine, Volume 390, Issue 6, Page 548-548, February 2024.
February 3, 2024: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.